Reinforcing effects of methamphetamine in an animal model of Attention-Deficit/Hyperactivity Disorder-the Spontaneously Hypertensive Rat

Behavioral and Brain Functions

Volumn 6, Issue , 2010, Pages

  dela Peña, Ike ^a   Ahn, Hyung S ^a   Choi, Ji Y ^a   Shin, Chan Y ^b   Ryu, Jong H ^c   Cheong, Jae H ^a  

^a Sahmyook University   (South Korea)

^b Konkuk University   (South Korea)

^c Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

METHAMPHETAMINE;

ADOLESCENCE; ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DRUG ABUSE; DRUG SELF ADMINISTRATION; HAIRLESS RAT; HYPERTENSION; MALE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; RAT STRAIN; REINFORCEMENT; SPONTANEOUSLY HYPERTENSIVE RAT; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; GENETICS; PSYCHOLOGICAL ASPECT; SPECIES DIFFERENCE; WISTAR RAT;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTENSION; MALE; METHAMPHETAMINE; RATS; RATS, INBRED SHR; RATS, WISTAR; REINFORCEMENT (PSYCHOLOGY); SPECIES SPECIFICITY;

EID: 78649767919     PISSN: None     EISSN: 17449081     Source Type: Journal    
DOI: 10.1186/1744-9081-6-74     Document Type: Article

References (40)

1. Taylor E. Clinical foundations of hyperactivity research. Behav Brain Res 1998, 94:11-24. 10.1016/S0166-4328(97)00165-4, 9708835.
2. Himelstein J, Newcorn JH, Halperin JM. The neurobiology of attention-deficit hyperactivity disorder. Front Biosci 2000, 5:461-478.
3. Swanson J, McBurnett K, Christian D, Wigal T. Stimulant medications and the treatment of children with ADHD. Advances in Clinical Psychology 1995, 265-322. New York, NY: Plenum Press, Ollendick T, Prinz R.
4. Anderson JC, Williams S, McGee R, Silva PA. DSM-III disorders in preadolescent children. Prevalence in a large sample from the general population. Arch Gen Psychiatry 1987, 44:69-76.
5. Bird HR, Gould MS, Staghezza BM. Patterns of psychiatric comorbidity in a community sample of children aged 9 through 16 years. J Am Acad Child Adolesc Psychiatry 1993, 32:361-368. 10.1097/00004583-199303000-00018, 8444766.
6. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greehill L, Howes MJ, Secnik K, Spencer T, Ustun TB, Walters EE, Zaslavsky AM. The prevalence and correlates of adult ADHD in the United: results from the national Comorbidity Survey Replication. Am J Psychiatry 2006, 163(4):716-23. 10.1176/appi.ajp.163.4.716, 2859678, 16585449.
7. Wilens T, Spencer T. The stimulants revisited. Child Adolesc Psychiatric Clin North Am 2000, 9:573-603.
8. Gordon SM, Tulak F, Troncale J. Prevalence and characteristics of adolescents patients with co-occurring ADHD and substance dependence. J Addict Dis 2004, 23(4):31-40. 10.1300/J069v23n04_03, 15339712.
9. Ohlmeier MD, Peters K, Te Wildt BT, Zedler M, Ziegenbein M, Wiese B, Emrich HM, Schneider U. Comorbidity of alcohol and substance dependence with attention-deficit/hyperactivity disorder (ADHD). Alcohol Alcohol 2008, 43(3):300-4.
10. Feltenstein MW, See RE. The neurocircuitry of addiction: an overview. Br J Pharmacol 2008, 154(2):261-74. 10.1038/bjp.2008.51, 2442446, 18311189.
11. Kohnke MD. Approach to the genetics of alcoholism: a review based on pathophysiology. Biochem Pharmacol 2008, 75(1):160-77. 10.1016/j.bcp.2007.06.021, 17669369.
12. Vendruscolo LF, Izidio GS, Takahashi RN. Drug reinforcement in a rat model of attention deficit/hyperactivity disorder- the spontaneously hypertensive rat (SHR). Curr Drug Abuse Rev 2009, 2:177-183. 10.2174/1874473710902020177, 19630747.
13. Sagvolden T, Russell VA, Aase H, Johansen EB, Farshbaf M. Rodent models of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005, 57(11):1239-47. 10.1016/j.biopsych.2005.02.002, 15949994.
14. Rat Genome Database. 2008, http://rgd.mcw.edu
15. Sagvolden T, Johansen EB, Wøien G, Walaas SI, Storm-Mathisen J, Bergersen LH, Hvalby O, Jensen V, Aase H, Russell VA, Killeen PR, Dasbanerjee T, Middleton FA, Faraone SV. The spontaneously hypertensive rat model of ADHD--the importance of selecting the appropriate reference strain. Neuropharmacol 2009, 57(7-8):619-26.
16. Tzschentke TM. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 2007, 12:227-462. 10.1111/j.1369-1600.2007.00070.x, 17678505.
17. Pamplona FA, Vendruscolo LF, Takahashi RN. Increased sensitivity to cocaine-induced analgesia in Spontaneously Hypertensive rats (SHR). Behav Brain Funct 2007, 3:9. 10.1186/1744-9081-3-9, 1802084, 17298672.
18. Pandolfo P, Pamplona F, Prediger R, Takahashi R. Increased sensitivity of adolescent spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder, to the locomotor stimulation induced by cannabinoid receptor agonist WIN 55,212-2. Eur J Pharmacol 2007, 563:141-148. 10.1016/j.ejphar.2007.02.013, 17374533.
19. Pandolfo P, Vendruscolo L, Sordi R, Takahashi R. Cannabinoid-induced conditioned place preference in the spontaneously hypertensive rat-an animal model of attention deficit hyperactivity disorder. Psychopharmacol 2009, 205:319-326.
20. Chambers R, Taylor JR, Potenza MN. Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry 2003, 160:1041-1052. 10.1176/appi.ajp.160.6.1041, 2919168, 12777258.
21. Sullivan MA, Rudnik-Levin F. Attention deficit/hyperactivity and substance abuse. Diagnostic and therapeutic considerations. Ann NY Acad Sci 2001, 931:251-270. 10.1111/j.1749-6632.2001.tb05783.x, 11462745.
22. Schubiner H. Substance abuse in patients with attention-deficit hyperactivity disorder: therapeutic implications. CNS Drugs 2005, 19:643-655. 10.2165/00023210-200519080-00001, 16097847.
23. dela Pena IC, Ahn HS, Choi JY, Shin CY, Ryu JH, Cheong JH. Methylphenidate self-administration and conditioned place preference in an animal model of attention deficit hyperactivity disorder-the spontaneously hypertensive rat. Behav Pharmacol
24. Merirrine E, Kankaanpaa A, Seppala T. Rewarding properties of methylphenidate: sensitization by prior exposure to the drug and effects of dopamine D1- and D2- receptor antagonists. J Phamacol Exp Ther 2001, 298:539-550.
25. Da Silva GE, Vendruscolo LF, Takahashi RN. Effects of ethanol on locomotor and anxiety-like behaviors and the acquisition of ethanol intake in Lewis and spontaneously hypertensive rats. Life Sci 2005, 77(6):693-706. 10.1016/j.lfs.2005.01.013, 15922000.
26. Blum K, Braverman E, Comings D, Chen T, Arcuri V, Blum S, Downs B, Waite R, Notaro A, Lubar J, Williams L, Prihoda T, Palomo T, Oscar-berman M. Attention-deficit-hyperactivity disorder and reward deficiency syndrome. Neuropsychiatr Dis Treat 2008, 4(5):893-917. 2626918, 19183781.
27. Clure C, Brady K, Saladin M, Johnson D, Waid R, Rittenbury M. Attention-deficit/hyperactivity disorder and substance use: symptom pattern and drug choice. Am J Drug Alcohol Abuse 1999, 25(3):441-448. 10.1081/ADA-100101871, 10473007.
28. Jaffe C, Bush KR, Straits-Troster K, Meredith C, Romwall L, Rosenbaum G, Cherrier M, Saxon AJ. A comparison of methamphetamine-dependent inpatients childhood attention deficit hyperactivity disorder symptomatology. J Addict Dis 2005, 24(3):133-52. 10.1300/J069v24n03_11, 16186089.
29. Yang PB, Amini B, Swann AC, Dafny N. Strain differences in the behavioral responses of male rats to chronically administered methylphenidate. Brain Res 2003, 971(2):139-52. 10.1016/S0006-8993(02)04240-3, 12706230.
30. Amini B, Yang PB, Swann AC, Dafny N. Differential locomotor responses in male rats from three strains to acute methylphenidate. Int J Neurosci 2004, 114(9):1063-83. 10.1080/00207450490475526, 15370174.
31. Tsai CF, Lin MT. Locomotor hyperactivity in hypertensive rats. Pharmacol 1988, 36(1):27-34.
32. Diaz Heijtz R, Castellanos FX. Differential effects of a selective dopamine D1-like receptor agonist on motor activity and c-fos expression in the frontal-striatal circuitry of SHR and Wistar-Kyoto rats. Behav Brain Funct 2006, 2:18. 10.1186/1744-9081-2-18, 1524794, 16729883.
33. van den Buuse M, de Jong W. Differential effects of dopaminergic drugs on open-field behavior of spontaneously hypertensive rats and normotensive Wistar-Kyoto rats. J Pharmacol Exp Ther 1989, 248(3):1189-96.
34. Riddle EL, Fleckenstein AE, Hanson GR. Role of monoamine transporters in mediating psychostimulant effects. AAPS J 2005, 7(4):E847-E851. 10.1208/aapsj070481, 2750953, 16594636.
35. Biederman J, Wilens T, Mick E, Faraone SV, Weber W, Curtis S, Thornell A, Pfister K, Jetton JG, Soriano J. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adol Psychiatry 1997, 36(1):21-29.
36. Bardo MT, Bevins A. Conditioned place preference:what does it add to our preclinical understanding of drug reward?. Psychopharmacol 2000, 153(1):31-43.
37. Williams JS. Researchers Probe for Clues to ADHD Medications' Protective Effects. NIDA Notes 2003, 18(1):11-13.
38. Stefanski R, Ladenheim B, Lee SH, Cadet JL, Goldberg SR. Neuroadaptations in the dopaminergic system after active selfadministration but not after passive administration of methamphetamine. Eur J Pharmacol 1999, 371:123-135. 10.1016/S0014-2999(99)00094-1, 10357249.
39. Iversen SD 5-HT and anxiety. Neuropharmacol 1984, 23:1553-1560. Iversen SD.
40. Green AR, McGregor IS. On the anxiogenic and anxiolytic nature of long-term cerebral 5-HT depletion following MDMA. Psychopharmacol 2002, 162:448-450.